SeaStar was formed only recently in 2018 when CytoPherx acquired immunocept Medical Products and subsequently changed their name to SeaStar. It is led by Dr. Charles Fisher, who is a director on AEMD's board. SeaStar received 510k clearance for AKI, pulmonary edema and congestive heart failure targets a very specific market - organ preservation in the solid organ transplant market. Recently SeaStar and Aethlon Medical have a joint venture arrangement and with the recent Covid-19 authorized study are looking to expand into the area where Cytosorb is already well entrenched and proven.
I don't have much other information on the product differences as there is very little information I can find. I know that is is hollow fiber based instead of polymer beads and I would almost bet it has no where near the surface area of Cytosorb nor can it remove as broad a spectrum of cytokines.
This is the only reference I can find from company filings and my notes - it was from an old 2015 10k when it was still CytoPherx:
"CytoPherx Inc., has developed an extracorporeal system based on selective cytapheresis, or the inactivation or removal of activated leukocytes. It was enrolling a 344 patient pivotal trial that began in August 2011 and was expected to be completed by December 2014 in patients with acute kidney injury with or without severe sepsis, on continuous renal replacement therapy with the goal of reducing mortality. This system does not remove cytokines directly, but attempts to reduce the numbers of activated white blood cells that can produce cytokines or cause cell-mediated injury"
Hope this helps.
News 
Market Data 
Discover 
